Latest News & Features
Refine Search
Americas
 AMAG Pharmaceuticals, Inc. has had a US patent covering ferumoxytol extended.   9 June 2014 
Biotechnology
 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.   9 June 2014 
Big Pharma
 Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report.   6 June 2014 
Americas
 Pfizer and Mylan have agreed to settle litigation related to arthritis treatment Celebrex (celecoxib), Mylan announced today, June 2.   2 June 2014 
Americas
 The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial	scrutiny, but practitioners need to keep	tabs	on court decisions, says Courtenay C. Brinckerhoff.   30 May 2014 
Europe
 London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy.   30 May 2014 
Europe
 London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative.   30 May 2014 
Americas
 With	the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions,	Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela	Rasheed	sums up the implications.   30 May 2014 
Big Pharma
 A pharmaceutical company in Turkey has run into trouble after attempting to register the Turkish word for ‘pharmacist’ as a trademark.   29 May 2014 
Big Pharma
 Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.   28 May 2014 


